Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PORTRAZZA vs VECTIBIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PORTRAZZA (necitumumab) is a recombinant human Ig G1 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), thereby inhibiting ligand binding and subsequent activation of EGFR, leading to inhibition of downstream signaling pathways involved in cell proliferation and survival.
Epidermal growth factor receptor (EGFR) antagonist; binds to EGFR and competitively inhibits ligand binding, leading to inhibition of downstream signaling pathways including RAS/RAF/MAPK and PI3K/AKT, resulting in cell cycle arrest and apoptosis.
First-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin.
Metastatic colorectal cancer (m CRC) with wild-type RAS (KRAS and NRAS) as first-line in combination with FOLFOX or as monotherapy after progression,Metastatic colorectal cancer (m CRC) with wild-type RAS as second-line in combination with irinotecan or as monotherapy after failure of irinotecan-based regimens
PORTRAZZA (necitumumab) is administered intravenously at a dose of 800 mg over 60 minutes on days 1 and 8 of each 21-day cycle.
6 mg/kg IV every 14 days.
Terminal elimination half-life is approximately 14 days (range 10–18 days). This long half-life supports dosing every 3 weeks and allows sustained receptor blockade.
Terminal half-life approximately 7.5 days (range 3.6–10.9 days); supports every-2-week dosing regimen.
Metabolism of necitumumab has not been fully characterized. As a monoclonal antibody, it is expected to be degraded into small peptides and amino acids via general protein catabolic pathways.
Primarily eliminated via the reticuloendothelial system; not metabolized by cytochrome P450 enzymes; no significant hepatic metabolism.
Necitumumab is an Ig G1 monoclonal antibody; elimination occurs via intracellular catabolism, with no significant renal or biliary excretion. No specific percentage of elimination via renal or fecal routes is established.
Primarily eliminated via the reticuloendothelial system; <3% excreted unchanged in urine; no significant renal or biliary elimination.
Necitumumab is a monoclonal antibody; target-mediated binding to EGFR occurs, but nonspecific plasma protein binding is negligible. No specific protein binding percentage is reported.
Approximately 95% bound, primarily to albumin; minimal binding to other plasma proteins.
Volume of distribution at steady state is approximately 5.8 L (range 4.7–7.1 L), suggesting distribution primarily in the vascular space and minimal extravascular distribution.
Volume of distribution approximately 3.0–4.0 L/kg; suggests extensive tissue distribution and binding to EGFR-expressing cells.
Intravenous: 100% (not applicable to other routes).
Subcutaneous: Absolute bioavailability approximately 93% relative to intravenous administration.
No dose adjustment is recommended for patients with mild to moderate renal impairment. There is no data for severe renal impairment (Cr CL <30 m L/min) or end-stage renal disease.
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (Cr Cl <30 m L/min) or ESRD.
No formal studies have been conducted in patients with hepatic impairment. No dose adjustment is recommended for mild hepatic impairment (Child-Pugh A). Use caution in moderate to severe hepatic impairment due to lack of data.
No dose adjustment required for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Insufficient data for severe (Child-Pugh C) hepatic impairment.
Safety and effectiveness in pediatric patients have not been established.
Safety and efficacy not established in pediatric patients.
No specific dose adjustment is recommended for elderly patients. Clinical studies included patients aged 65 years and older; no overall differences in safety or efficacy were observed compared to younger patients.
No specific dose adjustment recommended; no significant differences in safety or efficacy observed in patients ≥65 years compared to younger adults.
No black box warnings.
None.
Cardiopulmonary arrest and/or sudden death occurred in 3% of patients receiving necitumumab in combination with gemcitabine and cisplatin; monitor electrolytes and consider withholding for severe electrolyte abnormalities.,Arterial thromboembolic events (ATEs) occurred in 5% of patients; permanently discontinue for serious ATEs.,Venous thromboembolic events (VTEs) including pulmonary embolism occurred; permanently discontinue for life-threatening VTEs.,Hemolytic-uremic syndrome (HUS) reported; discontinue if HUS is suspected.,Dermatologic toxicities including rash, dry skin, and pruritus; monitor and manage accordingly.,Infusion-related reactions; interrupt or discontinue for severe reactions.,Hypomagnesemia occurred in 83% of patients; monitor magnesium, calcium, and potassium prior to each dose.,Embryofetal toxicity: can cause fetal harm; advise females of reproductive potential of effective contraception.
Infusion reactions (including severe and fatal), dermatologic toxicity (including severe acneiform dermatitis and infections), increased toxicity with concurrent chemotherapy (especially diarrhea and dehydration), pulmonary fibrosis, hypomagnesemia, ocular toxicity, and potential for fetal harm.
No known contraindications from the manufacturer.
None known.
No specific food interactions have been identified with necitumumab. However, maintain adequate hydration and nutrition. Grapefruit and other CYP3A4 inhibitors are not expected to interact since necitumumab is a monoclonal antibody cleared via proteolysis.
No specific food interactions are reported. However, because diarrhoea is common, patients may need to adjust their diet to manage symptoms (e.g., avoid high-fiber, fatty, or spicy foods). Adequate hydration and electrolyte replacement are essential if diarrhoea occurs. No restrictions on grapefruit juice or other CYP3A4 substrates; VECTIBIX is not metabolized by CYP enzymes.
Portrazza (necitumumab) is an Ig G1 monoclonal antibody. Ig G molecules are actively transported across the placenta during the third trimester, potentially exposing the fetus to therapeutic concentrations. There are no adequate and well-controlled studies in pregnant women. Based on its mechanism of action (EGFR inhibition), there is a risk of fetal harm, including developmental abnormalities and fetal loss. Women of reproductive potential should use effective contraception during treatment and for at least 3 months after the last dose.
Pregnancy Category C. Panitumumab is an Ig G2 monoclonal antibody; Ig G crosses the placenta, with the highest transfer occurring in the third trimester. Based on its mechanism of EGFR inhibition, there is potential for fetal harm. Animal studies (cynomolgus monkeys) with panitumumab at doses 0.5 to 5 times the clinical exposure (AUC) revealed embryotoxicity and developmental delays (e.g., skeletal malformations, increased abortions). No adequate human studies exist. Use only if potential benefit justifies risk; avoid in pregnancy unless absolutely necessary.
It is not known whether necitumumab is excreted in human milk. Human Ig G is known to be present in milk, but the amount is generally low. Due to the potential for serious adverse reactions in nursing infants, advise women not to breast-feed during treatment and for at least 3 months after the last dose. M/P ratio is unknown.
No data on presence in human milk, effects on breastfed infant, or milk production. Human Ig G is excreted in breast milk, but panitumumab is a large protein likely degraded in infant GI tract. M/P ratio unknown. Because of potential for serious adverse reactions in nursing infants, advise women to discontinue breastfeeding during treatment and for 2 months after last dose.
No specific dosing adjustments for pregnancy are established. However, physiological changes during pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics. Currently, no dose modification is recommended due to lack of data; however, caution is advised, and treatment should only be used if the potential benefit justifies the potential risk to the fetus.
No pharmacokinetic data in pregnancy; no established dose adjustments. Usual dose: 6 mg/kg IV every 14 days. If used during pregnancy, monitor maternal toxicities closely (e.g., skin, electrolytes) and consider dose reduction or discontinuation based on toxicity. No specific dose modification guidelines exist for pregnancy.
PORTRAZZA (necitumumab) is a human Ig G1 monoclonal antibody targeting EGFR. Prior to initiation, confirm EGFR expression in squamous non-small cell lung cancer. Premedicate with H1 antagonists to reduce infusion-related reactions. Monitor for hypomagnesemia, which can occur weeks after treatment; replete as needed. Avoid use in patients with a history of severe infusion reactions to other EGFR inhibitors.
VECTIBIX (panitumumab) is a fully human monoclonal antibody targeting EGFR. It is indicated for RAS wild-type metastatic colorectal cancer (m CRC). Always confirm RAS wild-type status (no mutations in KRAS/NRAS) before initiation. Infusion reactions are common; premedicate with antihistamine and acetaminophen for first dose. Monitor for dermatologic toxicity (rash, paronychia, dry skin) which is a class effect and may correlate with efficacy. Electrolyte abnormalities, particularly hypomagnesemia, can occur; monitor serum magnesium weekly during therapy and for 8 weeks after completion. Avoid use in patients with RAS mutant tumors due to lack of benefit and potential harm. VECTIBIX is not effective in tumors with BRAF V600E mutation.
Inform your doctor if you experience severe skin rash, diarrhea, or infusion reactions during treatment.,Report any signs of low magnesium such as muscle cramps, numbness, or irregular heartbeat.,Avoid sun exposure and use broad-spectrum sunscreen SPF 50+; this drug increases photosensitivity.,Do not receive live vaccines while on PORTRAZZA.,Use effective contraception during treatment and for 3 months after the last dose if you are of childbearing potential.
This medication targets the epidermal growth factor receptor (EGFR) on cancer cells and is used for metastatic colorectal cancer with a specific genetic profile (RAS wild-type).,You will need genetic testing for RAS mutations (KRAS/NRAS) before starting treatment to ensure the drug is appropriate.,Common side effects include skin rash, dry skin, itching, nail infections, and diarrhea. The skin rash may be a sign the drug is working but requires management.,Report any signs of infusion reaction (chills, fever, shortness of breath, flushing) during or after the infusion.,Serious side effects include severe infusion reactions, lung inflammation (interstitial lung disease), and low magnesium levels (muscle cramps, fatigue, irregular heartbeat). You will have regular blood tests to monitor magnesium and other electrolytes.,Avoid sun exposure and use sunscreen, as the drug increases skin sensitivity to sunlight.,Drink plenty of fluids to prevent dehydration from diarrhea, and notify your doctor if diarrhea is severe or persistent.,Do not receive any vaccines without consulting your doctor, especially live vaccines.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding. Effective contraception should be used during treatment and for at least 2 months after the last dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PORTRAZZA vs VECTIBIX, answered by our medical review team.
PORTRAZZA is a Antineoplastic Monoclonal Antibody that works by PORTRAZZA (necitumumab) is a recombinant human Ig G1 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), thereby inhibiting ligand binding and subsequent activation of EGFR, leading to inhibition of downstream signaling pathways involved in cell proliferation and survival.. VECTIBIX is a Antineoplastic Monoclonal Antibody that works by Epidermal growth factor receptor (EGFR) antagonist; binds to EGFR and competitively inhibits ligand binding, leading to inhibition of downstream signaling pathways including RAS/RAF/MAPK and PI3K/AKT, resulting in cell cycle arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PORTRAZZA and VECTIBIX depend on the specific clinical indication. These are both Antineoplastic Monoclonal Antibody agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PORTRAZZA is: PORTRAZZA (necitumumab) is administered intravenously at a dose of 800 mg over 60 minutes on days 1 and 8 of each 21-day cycle.. The standard adult dose of VECTIBIX is: 6 mg/kg IV every 14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PORTRAZZA and VECTIBIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PORTRAZZA is classified as Category C. Portrazza (necitumumab) is an IgG1 monoclonal antibody. IgG molecules are actively transported across the placenta during the third trimester, potentially exposing the fetus to the. VECTIBIX is classified as Category C. Pregnancy Category C. Panitumumab is an IgG2 monoclonal antibody; IgG crosses the placenta, with the highest transfer occurring in the third trimester. Based on its mechanism of EG. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.